Semaglutide

Independent reference data for Semaglutide (CAS 910463-68-2), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis. Semaglutide (available as bothSemaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. Due to the increased complexity involved, special attention is necessary for every FDA-approved indication and current off-label use.

Synonyms and trade names

Semaglutide; 910463-68-2; Rybelsus; Ozempic; Wegovy; NN9535; NN 9535; NNC 0113-0217; 53AXN4NNHX; NN-9535; CHEBI:167574; DTXSID101027903; NNC-0113-0217; semaglutida; semaglutidum; Oral Semaglutide

GHS hazard classification

Reported hazard statements	H302, H312, H332 (12.5%), H315 (12.5%), H319 (12.5%), H351 (25%), H361 (62.5%), H373 (12.5%)

H302+H312+H332 (12.5%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]

H302 (12.5%): Harmful if swallowed [Warning Acute toxicity, oral]

What the public record says

Semaglutide · CAS 910463-68-2 · C187H291N45O59. UNII 53AXN4NNHX. Solubility: <1 mg/mL.

Source: PubChem / Wikidata; the batch COA governs where values differ.